

Name : Aditya Shirish Adhav
Designation : Jr. Consultant



Qualification Details:-

MS, FBS

Topic of Dissertation:-

CLINICO-PATHOLOGICAL STUDY OF NON NEOPLASTIC
AND NEOPLASTIC LESIONS OF BREAST WITH
RADIOLOGICAL CORRELATION.

Senior resident

SMBT Hospital Nasik 18th Dec 2014
to 28th Jan 2015

Bharati Vidyapeeth Deemed
University, Pune 2nd March
2015 to 30th June 2015.

Fellowship

Breast surgery at Manavata
Curie Cancer Centre, Nashik
affiliated with Maharashtra
University of Health Sciences
from 2nd July 2015 to 31st Aug
2016.

Paper Presentation

- Male Breast Lesions: A Scenario at our institute

Poster Presentation

- Benign Multicystic Peritoneal Mesothelioma
- Aesthetics in Breast Surgery
- Rare But There: Male Breast Cancer

Publications in Indexed Journal

- Benign Multicystic Peritoneal Mesothelioma
- Amyand's Hernia A Rare Sliding Hernia
- Rare But There: Male Breast Cancer.
- Intracystic Papillary Carcinoma Of Breast: A Case Report.
- Anterior Mediastinal Mass: A Case Report Of Thymoma With Myasthenia Gravis.
- Kikuchi Fujimoto Disease: A Rare Benign Disease.

Conferences Attended

1. Attended **MASICON 2012** in **Pune**.
2. Poster presentation "**Benign Multicystic Peritoneal Mesothelioma**" in Nashik **MASICON 2013**.
3. Attended **ASICON** at **Ahmedabad** in **2013**.
4. Paper presentation "**Male Breast Lesions: A Scenario at our institute**" at **MASICON 2014**.
5. Organised and attended Live Operative workshop and Multidisciplinary CME on Breast Surgery at Curie Manavata Cancer Centre Nashik October 2015.
6. Attended Current trends in Oncology Breast Chapter - 2016 at Ruby Hall Clinic, Pune.

PRINCIPAL INVESTIGATOR IN

1) A Randomised double-blind study in two parts Part A – Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B – Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC).

2) A Randomized, Double-Blind, Multi- Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Paclitaxel Administered as First-Line Treatment in Patients with HER2 - Positive Metastatic Breast Cancer.

3) A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) And Abraxane[®] In Subjects With Locally Recurrent Or Metastatic Breast Cancer

SUB INVESTIGATOR IN

1) Prospective, multi-centric, randomized open-label, twoarm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR- 033 / Erbitux[®] in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.

2) A Prospective, Randomized, Multi- Centre Study to Compare the Safety, Tolerability, and Efficacy Bevacizumab (Zydus Cadila) With Bevacizumab (Avastin[®]) in Non-Small Cell Lung Cancer (NSCLC).

3) A Randomized, Double-blind, Placebo- controlled study to Evaluate the Long- term Safety and Efficacy of Darbepoetin Alpha Administered at 500mg once- Every-3- weeks in Anemic Subjects

with Advanced Stage Non-small cell Lung Cancer Receiving Multi-cycle Chemotherapy.

4) A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Inta Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non - Small Cell Lung Cancer.